ATE315939T1 - Verfahren zur prophylaxe oder kontrolle des katarakts - Google Patents

Verfahren zur prophylaxe oder kontrolle des katarakts

Info

Publication number
ATE315939T1
ATE315939T1 AT95900556T AT95900556T ATE315939T1 AT E315939 T1 ATE315939 T1 AT E315939T1 AT 95900556 T AT95900556 T AT 95900556T AT 95900556 T AT95900556 T AT 95900556T AT E315939 T1 ATE315939 T1 AT E315939T1
Authority
AT
Austria
Prior art keywords
cataract
prophylaxis
control
tgfbeta
relates
Prior art date
Application number
AT95900556T
Other languages
English (en)
Inventor
Johnston William Mcavoy
Coral Gwenda Chamberlain
Original Assignee
Univ Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sydney filed Critical Univ Sydney
Application granted granted Critical
Publication of ATE315939T1 publication Critical patent/ATE315939T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95900556T 1993-11-19 1994-11-11 Verfahren zur prophylaxe oder kontrolle des katarakts ATE315939T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPM254093 1993-11-19

Publications (1)

Publication Number Publication Date
ATE315939T1 true ATE315939T1 (de) 2006-02-15

Family

ID=3777368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900556T ATE315939T1 (de) 1993-11-19 1994-11-11 Verfahren zur prophylaxe oder kontrolle des katarakts

Country Status (6)

Country Link
US (1) US20030130324A1 (de)
EP (1) EP0735895B1 (de)
JP (1) JPH09505057A (de)
AT (1) ATE315939T1 (de)
DE (1) DE69434617D1 (de)
WO (1) WO1995013827A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
EP0958815A4 (de) * 1996-10-14 2001-02-07 Kissei Pharmaceutical Hemmer des sekundären katarakts
AUPO427196A0 (en) 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
JP5583310B2 (ja) * 2002-12-20 2014-09-03 チャクシュ・リサーチ・インコーポレーテッド 眼球の症状の予防及び治療のための眼科用製剤
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US8802651B2 (en) * 2004-06-30 2014-08-12 Abbott Medical Optics Inc. Hyaluronic acid in the enhancement of lens regeneration
US20060083732A1 (en) * 2004-06-30 2006-04-20 Arlene Gwon Hyaluronic acid in the enhancement of lens regeneration
US20080075756A1 (en) * 2004-06-30 2008-03-27 Advanced Medical Optics, Inc. Enhancement of lens regeneration using materials comprising polymers
US7794697B2 (en) * 2004-06-30 2010-09-14 Abbott Medical Optics Inc. Enhancement of lens regeneration using materials comprising polysiloxane polymers
US20070021505A1 (en) * 2005-07-15 2007-01-25 Chakshu Research, Inc Prevention and treatment of ophthalmic complications of diabetes
LT2915529T (lt) 2008-05-07 2018-10-25 The Regents Of The University Of California Gydomasis akių paviršiaus sutepimo atstatymas ir praturtinimas
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
US10138485B2 (en) 2008-09-22 2018-11-27 Rxi Pharmaceuticals Corporation Neutral nanotransporters
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
JP2013513622A (ja) 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ 白内障及び老眼を阻害する方法
AU2011232365A1 (en) 2010-03-24 2012-10-25 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
CN105209033B (zh) 2013-03-14 2018-09-18 马萨诸塞大学 抑制白内障和老花眼的方法
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
ES2745291T3 (es) 2015-11-13 2020-02-28 Univ Massachusetts Moléculas difuncionales que contienen PEG para su uso en la inhibición de cataratas y presbicia

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61233622A (ja) * 1985-04-09 1986-10-17 Riken Vitamin Co Ltd 眼薬組成物
SU1500254A1 (ru) * 1986-01-10 1989-08-15 Ростовский медицинский институт Способ прогнозировани осложнений после операции экстракции стационарных травматических катаракт
US5290813A (en) * 1987-06-04 1994-03-01 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
US5338545A (en) * 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US5401880A (en) * 1987-06-04 1995-03-28 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
EP0316438B1 (de) * 1987-06-04 1993-09-01 Massachusetts Institute Of Technology Chemisches verhindern oder rückgängigmachen von star-erkrankungen durch phasentrennungsinhibitoren
FR2627078B1 (fr) * 1988-02-16 1994-03-18 Allergan Inc Dispositif oculaire
ATE119038T1 (de) * 1988-12-09 1995-03-15 Allergan Inc Verwendung von 2-substituierten thiazolidin-4- carbonsäuren zur behandlung von katarakt.
ATE147613T1 (de) * 1989-09-15 1997-02-15 Chiron Vision Corp Synthetisches material, das die anlagerung, das wachstum und die befestigung von epithelzellen fördert, prosthetische vorrichtung zur subepithelialen implantation sowie behandelte linse
JPH0780780B2 (ja) * 1989-09-29 1995-08-30 ラ ホヤ キャンサー リサーチ ファウンデーション 細胞外マトリックスの蓄積防止のためのトランスフォーミング増殖因子βの阻害
CA2039420C (en) * 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
US5164187A (en) * 1990-04-05 1992-11-17 Norian Corporation Hydroxyapatite prosthesis coatings
ATE139683T1 (de) * 1990-12-03 1996-07-15 Adatomed Pharma Chiron Intraokulare künstliche augenlinse
IT1249047B (it) * 1991-02-21 1995-02-11 Zambon Spa Composizione farmaceutica per il trattamento della cataratta
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
IT1251838B (it) * 1991-09-20 1995-05-26 Lpb Ist Farm Uso della nimesulide nel trattamento della cataratta
AU669132B2 (en) * 1991-10-11 1996-05-30 Mark Cedric Gillies Treating ophthalmic fibrosis using interferon-alpha
EP0667784B1 (de) * 1991-11-14 2003-03-05 La Jolla Cancer Research Foundation Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung
WO1993010808A1 (en) * 1991-12-04 1993-06-10 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
AU3943793A (en) * 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
AU4111893A (en) * 1992-04-23 1993-11-29 La Jolla Cancer Research Foundation Methods for treating vascular disorders by inhibiting the endothelin stimulatory activity of TGFbeta
WO1994001124A1 (en) * 1992-07-08 1994-01-20 Celtrix Pharmaceuticals, Inc. METHOD OF TREATING OPHTHALMIC DISORDERS USING TGF-$g(b)
US5589464A (en) * 1992-09-01 1996-12-31 Allergan Use of 2-substituted-thiazolidine-4-carboxylic acids for treatment of cataract
AU669256B2 (en) * 1992-10-29 1996-05-30 Celtrix Pharmaceuticals, Inc. Uses of TGF-beta receptor fragment as a therapeutic agent
AU5541094A (en) * 1992-10-30 1994-05-24 Consejo Superior De Investigaciones Cientificas Compositions and methods for modifying the regulatory activity of tgf-beta
TW354762B (en) * 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
CA2162586C (en) * 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
WO2000001410A1 (en) * 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis

Also Published As

Publication number Publication date
WO1995013827A1 (en) 1995-05-26
DE69434617D1 (de) 2006-04-06
EP0735895B1 (de) 2006-01-18
EP0735895A4 (de) 2001-03-28
US20030130324A1 (en) 2003-07-10
EP0735895A1 (de) 1996-10-09
JPH09505057A (ja) 1997-05-20

Similar Documents

Publication Publication Date Title
ATE315939T1 (de) Verfahren zur prophylaxe oder kontrolle des katarakts
ATE186307T1 (de) Verfahren zur reinigung von hyaluronsäure und fraktion von reiner hyaluronsäurezur ophthalmischen verwendung.
NZ255758A (en) Crosslinked polymeric ammonium salts useful as bile sequestrants
UA41275C2 (uk) Гербіцидна композиція та спосіб контролю росту небажаних рослин
DE59807122D1 (de) Verwendung von fumarsäurederivaten zur behandlung von autoimmunerkrankungen
AU6008894A (en) Hypolipidaemic compounds
MX9702272A (es) Inhibicion del crecimiento del cabello.
DE69423782D1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
DE59507342D1 (de) Verfahren zur herstellung von heterologen bispezifischen antikörpern
GR3034407T3 (en) Skin tanning compositions
DE69727839D1 (de) Verwendung von zusammensetzungen zur versorgung mit mineralien nach einer gastrotomie
ATE139809T1 (de) Verfahren zur korrosionsinhibierung in wässerigen systemen
ATE175999T1 (de) Verfahren zur regulierung von sialinsaeurederivaten in rekombinanten glykoproteinen
ATE127322T1 (de) Verfahren zur korrigierung und optimierung einer futterzusammensetzung.
DE69510775D1 (de) Methoden zur verwendung von cyclischenpolyanionischen polyderivatenzur kontrolle von hautfalten
ATE148074T1 (de) Verfahren zur kontrolle von schwingungen einer pendelnden last und vorrichtung zur durchführung des verfahrens
BG98761A (en) Substituted pyrroles
ATE201388T1 (de) Verfahren zur verbesserung der biozidaktivität
AU1503897A (en) Method for culturing microorganisms having methanol metabolic pathway
ATE206473T1 (de) Verfahren zur herstellung eines kornorientierten siliziumstahlblechs
DE69228814D1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE69535263D1 (de) Angiotensin ii zur verbesserung der befruchtung
CA2223692A1 (en) Emulsified compositions of 1,4-bis(bromoacetoxy)-2-butene useful as a microbicide and preservative
ATE101045T1 (de) Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen.
AU2001254634A1 (en) Use of neuregulin-beta as an indicator and/or target

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties